• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Arcadia Biosciences Inc.

    11/22/24 3:17:14 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples
    Get the next $RKDA alert in real time by email
    S-8 1 rkda-2024-s-8.htm S-8 S-8

     

    Registration Statement No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    THE SECURITIES ACT OF 1933

     

    ARCADIA BIOSCIENCES, INC.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

    81-0571538

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

    5950 Sherry Lane, Suite 215

    Dallas, TX 75225

    (Address of Principal Executive Offices) (Zip Code)

     

    2015 Omnibus Equity Incentive Plan

    2015 Employee Stock Purchase Plan

    (Full title of the plan)

     

    Thomas J. Schaefer

    President and Chief Executive Officer

    5950 Sherry Lane, Suite 215

    Dallas, TX 75225

    (214) 974-8921

    (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)

     

    Copies to:

    Mark Kawakami

    Chief Financial Officer

    5950 Sherry Lane, Suite 215

    Dallas, TX 75225

    Michael De Angelis, Esq.

    Jeffrey Pietsch, Esq.

    Weintraub Tobin Chediak Coleman Grodin Law Corporation

    400 Capitol Mall, Suite 1100

    Sacramento, CA 95814

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    

     

     

    Accelerated filer

    

    Non-accelerated filer

    

     

     

    Smaller reporting company

    

    Emerging growth company

     

    

     

     

     

     

     

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. 

     

     

     


     

    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (“Registration Statement”) is filed by Arcadia Biosciences, Inc. (“Registrant”) to register (i) an additional 546 shares of the Registrant’s common stock, $0.001 par value per share (“Common Stock”), that are issuable pursuant to the Registrant’s 2015 Employee Stock Purchase Plan, and (ii) an additional 251,413 shares of Common Stock that issuable pursuant to the Registrant’s 2015 Omnibus Equity Incentive Plan (“2015 Omnibus Plan”).

     

    PART I

     

    Information Required in the Section 10(a) Prospectus

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference

    The following documents filed by Registrant with the Securities and Exchange Commission (the “SEC”) are incorporated by reference into this Registration Statement:

    •
    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 28, 2024 (“Annual Report”);
    •
    Amendment No. 1 to the Registrant’s Annual Report on Form 10-K/A for the fiscal year ended December 31, 2023, filed with the SEC on April 29, 2024;
    •
    The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, from the Registrant’s Definitive Proxy Statement on Schedule 14A, filed with the SEC on May 16, 2024;
    •
    The Registrant’s Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2024, June 30, 2024 and September 30, 2024, filed with the SEC on May 13, 2024, August 13, 2024, and November 12, 2024, respectively;
    •
    The Registrant’s Current Reports on Form 8-K/A filed with the SEC on August 23, 2024 and Form 8-K filed with the SEC on February 14, 2024, March 28, 2024, May 9, 2024, May 17, 2024, May 20, 2024, July 1, 2024, July 8, 2024, August 7, 2024, August 13, 2024, and November 12, 2024;
    •
    All other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Annual Report; and
    •
    The description of the Registrant’s common stock contained in the Description of Registrant’s Securities filed as Exhibit 4.7 to the Annual Report, including any amendments or reports filed for purposes of updating such description.

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have


     

    been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    Section 145 of the Delaware General Corporation Law (the “DGCL”) provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending or completed actions, suits or proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise. The DGCL provides that Section 145 is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaws, agreement, vote of stockholders or disinterested directors or otherwise. The Registrant’s certificate of incorporation (the “Charter”) and amended and restated bylaws (the “Restated Bylaws”) provide for indemnification by the Registrant of its directors and officers to the fullest extent permitted by the DGCL.

    Section 102(b)(7) of the DGCL permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (1) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (2) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3) for unlawful payments of dividends or unlawful stock repurchases, redemptions or other distributions or (4) for any transaction from which the director derived an improper personal benefit. The Charter provides for such limitation of liability to the fullest extent permitted by the DGCL

    The Restated Bylaws provide that the Registrant must indemnify its directors and executive officers and may indemnify its employees and other agents to the fullest extent permitted by the DGCL.

    The Registrant has entered into indemnification agreements with its directors and executive officers, in addition to the indemnification provided for in its certificate of incorporation and bylaws, and intends to enter into indemnification agreements with any new directors and executive officers in the future.

    The Registrant has purchased and intends to maintain insurance on behalf of each and any person who is or was a director or officer of the Registrant against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.

    Item 7. Exemption from Registration Claimed.

    Not applicable.


     

    Item 8. Exhibits

     

    Exhibit
    No.

    Description of Exhibit

     

     

    4.1

     

    Amended and Restated Certificate of Incorporation (previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on May 26, 2015 and incorporated herein by reference).

    4.2

     

    Certificate of Amendment to the Certificate of Incorporation (previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on February 28, 2023 and incorporated herein by reference).

    4.3

     

    Amended and Restated Bylaws (previously filed as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on May 26, 2015 and incorporated herein by reference).

    4.4

     

    Amendment to the Amended and Restated Bylaws (previously filed as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on December 8, 2022 and incorporated herein by reference).

    5.1

    Opinion of Weintraub Tobin Chediak Coleman Grodin Law Corporation.

    99.1

     

    2015 Omnibus Equity Incentive Plan and form of agreement thereunder (previously filed as Exhibit 10.5 to the Registrant’s Quarterly Report on Form 10-Q filed on August 13, 2024 and incorporated herein by reference).

    99.2

     

    2015 Employee Stock Purchase Plan and form of agreement thereunder (previously filed as Exhibit 10.10 to the Registrant’s Registration Statement on Form S-1/A filed on May 11, 2015 and incorporated herein by reference).

    23.1

    Consent of Deloitte & Touche LLP, independent registered public accounting firm.

    23.2

    Consent of Weintraub Tobin Chediak Coleman Grodin Law Corporation (included in Exhibit 5.1).

    24.1

     

    Power of Attorney (included on the signature page to this Form S-8).

    107

     

    Filing Fee Table.

     

    Item 9. Undertakings.

     

    (a) The Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) (§ 230.424(b) of this chapter) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.

     

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.


     

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     


     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dallas, State of Texas, on this 22nd day of November, 2024.

    ARCADIA BIOSCIENCES, INC.

     

     

    By:

    /s/ MARK KAWAKAMI

    Name:

    Mark Kawakami

    Title:

    Chief Financial Officer

     

     


     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below constitutes and appoints Thomas J. Schaefer as his or her true and lawful attorney-in-fact and agent, with the power of substitution, for him/her and in his/her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that such attorney-in-fact and agent, or any substitute or substitutes for him, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    Signature

    Title

    Date

     

     

     

     

     

     

    /s/ THOMAS J. SCHAEFER

    President, Chief Executive Officer and Director

     

    Thomas J. Schaefer

    (principal executive officer)

    November 22, 2024

     

     

     

     

     

     

     

     

    /s/ MARK KAWAKAMI

    Chief Financial Officer

     

    Mark Kawakami

    (principal financial and accounting officer)

    November 22, 2024

     

     

     

     

     

     

     

     

    /s/ KEVIN COMCOWICH

     

     

    Kevin Comcowich

    Director

    November 22, 2024

     

     

     

     

     

     

     

     

    /s/ ALBERT D. BOLLES

     

     

    Albert D. Bolles

    Director

    November 22, 2024

     

     

     

     

     

     

     

     

    /s/ LILIAN SHACKELFORD MURRAY

     

     

     

     

    Lilian Shackelford Murray

     

    Director

     

    November 22, 2024

     

     

     

     

     

     

     

     

    /s/ GREGORY D. WALLER

     

     

    Gregory D. Waller

    Director

    November 22, 2024

     

     

     

     

     

     

     

     

    /s/ AMY YODER

     

     

    Amy Yoder

    Director

    November 22, 2024

     

     

     

     

     

     

     

     

     

     

    /s/ DEBORAH D. CAROSELLA

     

     

    Deborah D. Carosella

    Director

    November 22, 2024

     


    Get the next $RKDA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RKDA

    DatePrice TargetRatingAnalyst
    1/3/2022$7.00 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $RKDA
    SEC Filings

    View All

    SEC Form EFFECT filed by Arcadia Biosciences Inc.

    EFFECT - Arcadia Biosciences, Inc. (0001469443) (Filer)

    2/11/26 12:15:27 AM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Arcadia Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Arcadia Biosciences, Inc. (0001469443) (Filer)

    2/6/26 4:03:58 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    SEC Form S-3 filed by Arcadia Biosciences Inc.

    S-3 - Arcadia Biosciences, Inc. (0001469443) (Filer)

    1/27/26 8:45:16 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    $RKDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Kawakami Mark bought $1,743 worth of shares (700 units at $2.49), increasing direct ownership by 35% to 2,681 units (SEC Form 4)

    4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

    2/5/25 7:34:41 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Chief Executive Officer Schaefer Thomas J. bought $1,743 worth of shares (700 units at $2.49), increasing direct ownership by 33% to 2,819 units (SEC Form 4)

    4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

    2/5/25 7:24:18 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Chief Financial Officer Kawakami Mark bought $1,442 worth of shares (700 units at $2.06), increasing direct ownership by 55% to 1,981 units (SEC Form 4)

    4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

    8/20/24 8:11:11 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    $RKDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Arcadia Biosciences with a new price target

    HC Wainwright & Co. reiterated coverage of Arcadia Biosciences with a rating of Buy and set a new price target of $6.00 from $7.00 previously

    1/3/22 6:06:17 AM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    HC Wainwright & Co. reiterated coverage on Arcadia Biosciences with a new price target

    HC Wainwright & Co. reiterated coverage of Arcadia Biosciences with a rating of Buy and set a new price target of $7.00 from $6.00 previously

    6/1/21 6:50:30 AM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Lake Street initiated coverage on Arcadia Biosciences with a new price target

    Lake Street initiated coverage of Arcadia Biosciences with a rating of Buy and set a new price target of $4.50

    5/11/21 12:00:10 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    $RKDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arcadia Biosciences (RKDA) Announces Exercise of Preferred Investment Options for $2.1 Million Gross Proceeds

    DALLAS, Jan. 12, 2026 (GLOBE NEWSWIRE) --  Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, today announced that it has entered into definitive agreements for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 808,595 shares originally issued in December 2020, January 2021, August 2022 and March 2023, having an exercise price of $9.00 per share, at a reduced exercise price of $2.575 per share. The shares of common stock issuable upon exercise of the preferred investment options are registered pursuant to effective registration statements on Form S-1 (Registration Nos. 333-262407 and

    1/12/26 8:00:00 AM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Arcadia Biosciences (RKDA) Receives Termination Notice of the Proposed Business Combination with Roosevelt Resources

    DALLAS, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, today announced that on December 24, 2025, it received a notice from Roosevelt Resources, LP, terminating the Securities Exchange Agreement between Arcadia and Roosevelt dated December 4, 2024, pursuant to the terms of the agreement. The agreement provided for a proposed business combination transaction between the two companies. "In light of these circumstances, Arcadia will resume the process of evaluating strategic alternatives in order to create value for our shareholders." said T.J. Schaefer, CEO of Arcadia. Schaefer continued, "Over the last t

    12/26/25 8:02:00 AM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights

    -- Zola® year-to-date revenues increase 26% year over year ---- Arcadia gross profit margins exceed 30% for 11th straight quarter ---- Arcadia cash balance declines by only $257K to $1.1M -- DALLAS, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the third quarter of 2025. "We are very pleased with our performance for the third quarter of 2025." said T.J. Schaefer, CEO of Arcadia. "Zola® coconut water revenues were flat year-over-year in the third quarter as we overlapped the initial sell-in to Zola's largest customer during the third quarter of 2024

    11/7/25 4:05:00 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    $RKDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Kawakami Mark

    4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

    5/12/25 8:56:01 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    SEC Form 4 filed by Chief Executive Officer Schaefer Thomas J.

    4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

    5/12/25 8:48:31 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Chief Financial Officer Kawakami Mark bought $1,743 worth of shares (700 units at $2.49), increasing direct ownership by 35% to 2,681 units (SEC Form 4)

    4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

    2/5/25 7:34:41 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    $RKDA
    Leadership Updates

    Live Leadership Updates

    View All

    Arcadia Biosciences (RKDA) Announces Leadership Transition

    -- CEO Stan Jacot replaced by CFO Thomas J. Schaefer -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced that CEO Stan Jacot has left the company and been replaced by Thomas J. Schaefer, effective July 5, 2024. Schaefer was previously Arcadia's chief financial officer and will be replaced in that role by Mark Kawakami, Arcadia's current vice president of finance. "On behalf of Arcadia, I would like to thank Stan for his many contributions to the company," said Board of Directors Chairman Kevin Comcowich. "Under his leadership, Arcadia expanded the GoodWheat brand into three categories, sold the brand to

    7/9/24 8:02:00 AM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Arcadia Biosciences (RKDA) Appoints Kevin Comcowich to Interim CEO

    DAVIS, Calif., Dec. 20, 2021 /PRNewswire/ -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced it has appointed Kevin Comcowich, current Chairman of the Arcadia Board of Directors, as interim chief executive officer, effective January 1, 2022, as the board of directors finalizes its search for a permanent CEO. As previously announced on September 7, 2021, the board of directors launched a national search for a new CEO as the company further expands into the consumer packaged goods (CPG) sector.

    12/20/21 10:55:00 AM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Arcadia Biosciences (RKDA) Appoints Seasoned CPG Sales Executive Brian Schaffer to Senior Vice President of Sales

    DAVIS, Calif., Nov. 22, 2021 /PRNewswire/ --  Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced it has named Brian Schaffer as senior vice president of sales, as the company continues to expand its consumer goods platforms. A seasoned sales and general management executive with deep CPG experience, Schaffer has a proven track record of building and leading world class sales organizations. He is tasked with driving the retail launch of Arcadia's GoodWheat brand, a company priority in 2022 as it w

    11/22/21 8:00:00 AM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    $RKDA
    Financials

    Live finance-specific insights

    View All

    Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights

    -- Zola® year-to-date revenues increase 26% year over year ---- Arcadia gross profit margins exceed 30% for 11th straight quarter ---- Arcadia cash balance declines by only $257K to $1.1M -- DALLAS, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the third quarter of 2025. "We are very pleased with our performance for the third quarter of 2025." said T.J. Schaefer, CEO of Arcadia. "Zola® coconut water revenues were flat year-over-year in the third quarter as we overlapped the initial sell-in to Zola's largest customer during the third quarter of 2024

    11/7/25 4:05:00 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2025 Financial Results and Business Highlights

    -- Arcadia revenues increase 11% year over year driven by 24% growth in Zola® -- -- Arcadia receives 2.7 million shares of stock in ABVE -- -- Arcadia eliminates $1M in liabilities -- DALLAS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the second quarter and first half of 2025. "We are very pleased with our performance for the second quarter of 2025," said T.J. Schaefer, CEO of Arcadia. "While our total revenues have increased 11% compared to the second quarter of 2024, Zola® coconut water revenues have grown 24% and once aga

    8/14/25 4:30:00 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Arcadia Biosciences (RKDA) Announces First Quarter 2025 Financial Results and Business Highlights

    -- Revenues increase 22% year over year driven by 90% growth in Zola® ---- Arcadia sells patents for $750K and eliminates $1M in liabilities ---- Roosevelt agreement amended to provide greater certainty regarding exchange ratio -- DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the first quarter of 2025. The company has scheduled a conference call at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) to discuss first-quarter results and key strategic achievements. "The momentum we experienced in the second half of 2024 has

    5/8/25 8:02:00 AM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    $RKDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Arcadia Biosciences Inc. (Amendment)

    SC 13G/A - Arcadia Biosciences, Inc. (0001469443) (Subject)

    2/14/24 2:55:48 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    SEC Form SC 13G filed by Arcadia Biosciences Inc.

    SC 13G - Arcadia Biosciences, Inc. (0001469443) (Subject)

    1/3/24 12:26:00 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    SEC Form SC 13G filed by Arcadia Biosciences Inc.

    SC 13G - Arcadia Biosciences, Inc. (0001469443) (Subject)

    2/14/23 1:22:05 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples